Technology billionaire Sean Parker’s Institute for Cancer Immunotherapy collaboration has come up with its first major discovery in the cancer field. Scientists working with the institute may have uncovered a blood test method for predicting whether melanoma patients will respond to targeted treatments for the programmed cell death protein (PD-1) pathway in tumors, a paper in the journal Nature claims.
This test is not a cure for the disease. But it could benefit industry observers keeping their eyes on what exactly Parker’s organization can accomplish. The Nature paper is the first paper from the institute and could suggest what this collaborative method can accomplish when it comes to efforts to cure cancer.